Sellas reaches 80th event in Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia
SLS•Sellas Life Sciences said its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia reached its 80th event. The company expects to report topline primary endpoint results this quarter.
1. Trial reaches endpoint
Sellas Life Sciences Group said its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia reached its 80th event. The company said it plans to report topline primary endpoint results from the trial this quarter.
